Oncology

Genome-wide methylation profiling is transforming the way clinicians approach brain tumor diagnosis. By analyzing epigenetic patterns across the genome, this advanced testing method provides a new level of precision, helping resolve ambiguous cases, reduce diagnostic variability, and support more confident clinical decision-making in complex CNS tumors.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.

Autoimmune neurology testing has evolved beyond limited paraneoplastic evaluations to phenotype-specific panels that identify clinically relevant antibodies. This phenotype-specific approach significantly improves diagnostic accuracy, reduces false positives, and helps guide faster, more personalized treatment for complex neurological diseases.

Learn more about Mayo Clinic Laboratories’ new genome-wide methylation array from the Mayo Clinic neuro-oncology testing experts who worked alongside the National Institutes of Health to develop the innovative, first-in-class assay.

New wtRNA-seq test detects fusions in 1,445 genes with high accuracy, improving cancer diagnosis, treatment decisions, and clinical trial eligibility.

Research improves the diagnosis of rare Birt-Hogg-Dubé syndrome, closing genetic testing gaps, guiding care, and earning recognition as a top paper.

This microlearning provides a practical, structured approach to evaluating specimens for molecular testing using real examples and criteria drawn from laboratory practice to support confident, consistent decision-making.

Learn more about how Mayo Clinic Laboratories approach to whole transcriptome RNA sequencing provides the most comprehensive detection of gene fusions in solid tumors through use of next-generation sequencing to identify fusions in 1,445 genes.

LiquidHALLMARK combines DNA and RNA for more accurate cancer profiling, helping patients access lifesaving therapies.

Join us for a webinar exploring how LiquidHALLMARK®, a cutting-edge liquid biopsy test, is transforming cancer care.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.

PACE/State of FL - The role of cytology specimens in molecular genetic testing, emphasizing their effectiveness in identifying biomarkers critical for targeted therapies in patients with cancer.